The passage of proteins through the secretory pathway involves their orderly progression through a series of membranous compartments ([@B48]) and is mediated by vesicles that bud from one compartment and fuse with the next ([@B45]; [@B59]). Intracellular transport has been extensively studied using yeast genetics, cell-free assays, and neuronal synapses. The combined information indicates that most of the components of the machinery used in constitutive vesicular trafficking in yeast are related to the components that mediate neurotransmitter release ([@B7]; [@B13]). Models are beginning to emerge for the action of these components in vesicle budding and in vesicle targeting and fusion. Budding of vesicles is driven by cytosolic proteins that associate transiently with the membrane and form a coat complex. Different budding events in the secretory pathway are mediated by at least three types of coat complexes: clathrin, COPI, and COPII. Another class of coat proteins may be involved in budding of secretory vesicles from the TGN ([@B29]; [@B32]; [@B44]). GTP-binding proteins of the ARF/Sar1 family were shown to be part of the COPI and COPII coat complexes and/or to regulate the assembly and disassembly of these complexes through guanine nucleotide cycling ([@B59], [@B61]). After coat disassembly, a vesicle is targeted to the appropriate acceptor compartment. A current model for the molecular basis of this targeting reaction proposes the association of a specific vesicle-associated soluble *N*-ethylmaleimide--sensitive factor attachment protein (SNAP) receptor (v-SNARE)^1^ with a target-associated SNAP receptor (t-SNARE) ([@B59]; [@B60]).

The Ypt/rab/Sec4 family of small GTPases plays an important role in vesicular trafficking both in yeast and in mammalian cells. These GTPases are involved in the regulation of protein transport through the different steps of the exocytic, endocytic, and transcytotic pathways ([@B50]; [@B14]; [@B45]; [@B78]). An important question concerning the mode of action of Ypt/rab proteins is whether they function in vesicle budding, targeting, or fusion. Convincing evidence already exists for an important role for rab proteins in regulating vesicle targeting ([@B8]; [@B36]; [@B66]). In yeast, Ypt1p was shown to act after vesicle formation, in the targeting of vesicles to the acceptor compartment in the ER-to-Golgi step ([@B56]; [@B62]), and Sec4p was shown to act in the targeting of *trans*-Golgi--derived vesicles to the plasma membrane ([@B45]). However, whether Ypt/rab proteins also have a role in vesicle budding still needs to be resolved. Another question concerning Ypt/ rab GTPases is whether they regulate every step of intracellular protein transport. In mammalian cells several rab proteins, including rab1, rab2, rab3, rab6, rab8, and rab11, have been assigned to the different exocytic steps, based on intracellular localization studies and analysis of dominant mutants ([@B19]). In yeast, a number of Ypt proteins, including Ypt51-53p, Ypt6p, and Ypt7p, have been implicated in the endocytic pathway and in the sorting of proteins to the vacuole ([@B77]; Horazdovski et al., 1994). Interestingly, only two Ypt GTPases have been shown to function in the yeast exocytic pathway: Ypt1p in the first two steps ([@B64]; [@B2]; [@B3]; [@B27]) and Sec4p in the last step ([@B47]; [@B18]; [@B76]). In this paper, we wished to determine whether two newly identified Ypt proteins have a role in exocytic steps between those regulated by Ypt1p and Sec4p.

Two steps in the yeast exocytic pathway have been studied extensively: ER to *cis*- and *trans*-Golgi--derived vesicles to the plasma membrane. A large number of proteins that function in these secretory steps have been identified using genetic screens, but only a few proteins were identified as components of the machinery that functions at intermediate steps of the pathway, during protein transit through the Golgi complex ([@B46]; [@B1]; [@B4]). The compartmental organization of the yeast Golgi complex has been characterized primarily by using two mutants, *sec18* and *sec7*, and by cell fractionation studies ([@B11]; [@B15]; [@B20]). Three functionally distinct Golgi compartments have been defined that contain, from *cis* to *trans*: α-1,6mannosyltransferase, α-1,3-mannosyltransferase, and the Kex2 protease. However, very little is known about proteins that mediate and regulate transport between the Golgi compartments. To date, only Sec7p and Sec14p have been suggested to function exclusively within the yeast Golgi ([@B1]; [@B4]).

In this paper we report the identification of two new Ypt GTPases that belong to the exocytic Ypt/rab subfamily. Using inactivating mutations and intracellular localization experiments, we show that these two proteins have a role in secretory steps that lie between those regulated by Ypt1p and Sec4p and that involve transport through the *trans*-Golgi compartment. Our results suggest that the Ypt31/32 GTPases have a role in budding of vesicles from the *trans*-Golgi compartment. These findings provide the first in vivo indication that Ypt/rab GTPases may function not only in vesicle targeting, but also in vesicle budding. A possible implication of our data is that similar molecular processes underlie vesicle fusion and vesicle budding. Alternatively, Ypt31/32 might have a role in fusion of recycling vesicles with the *trans*-Golgi compartment, a process that is presumably necessary for exit from this compartment.

Materials and Methods
=====================

Yeast Strains, Media, and Reagents
----------------------------------

Yeast strains used in this study are listed in Table [I](#TI){ref-type="table"}. NSY313 was derived from NSY290 (*ypt31::HIS3*) in which the *ypt32A141D* mutation was targeted to the chromosome (see Site-directed Mutagenesis and Plasmid Construction). NSY 348 was derived from a backcross of NSY313 to NSY125. NSY 368 was derived from a cross of PNY504 to NSY348.

Yeast cultures were grown in synthetic medium (0.67% nitrogen base without amino acids) supplemented with the appropriate nutritional requirements or 5-fluoro-orotic acid (5-FOA) ([@B58]), and with glucose added to 2% (wt/vol).

Reagents were obtained from the following sources: Recombinant yeast lytic enzyme, Zymolyase 100T, and ^35^S-Translabel used for in vivo labeling were from ICN Pharmaceuticals Inc. (Irvine, CA). Secondary antibodies used for immunofluorescence were from Jackson ImmunoResearch (West Grove, PA). Rhodamine-phalloidin was from Molecular Probes (Eugene, OR). Horseradish peroxidase--conjugated goat anti--rabbit IgG used for Western blotting and the enhanced chemiluminescence detection kit were from Amersham International (Buckinghamshire, England). Immobilon-P membrane was from Millipore Corp. (Bedford, MA). Chemical reagents were purchased from Sigma Chemical Co. (St. Louis, MO). The following antibodies were kindly donated: antiinvertase by Chris Kaiser (Massachusetts Institute of Technology, Boston, MA); anti--carboxypeptidase Y (CPY) by Tom Stevens (University of Oregon, Eugene, OR); anti--α-factor by Tod Graham (Vanderbilt University, Nashville, TN); anti-α1,3 mannose by Alex Franzusoff (University of Colorado, Denver, CO).

Gene Deletion
-------------

Gene disruption was performed using PCR for replacement of the entire coding region with selectable markers, either *HIS3* ([@B6]) or the *kan^r^* gene ([@B75]). Oligonucleotides contained 35 bp of target homology at their ends and in all cases oligos were designed such that the structural gene was precisely deleted. For the deletion of *YPT31* using *HIS3* as a selectable marker, the following oligonucleotides were used: *YPT31-HIS3*-pro (GCA AAG GGA TTC TGA CGG CGT CTG GGG ATT TCA ACA CTC TTG GCC TCC TCT AG) and *YPT31-HIS3-*term (TCA CAT GCA AGT GCG CAA CTG CTG CAA AAT ATC TCT CGT TCA GAA TGA CAC G). The deletion of *YPT32* was executed using oligonucleotides *YPT32-HIS3*-pro (TGA TAA AGA GCG AAC CAA GCA TAT TGT TTT CCA AGA CTC TTG GCC TCC TCT AG) and *YPT32-HIS3*-term (GAC AGA TAT GCA TGA AAC CAT GCG ACC TTA GTA GGG TCG TTC AGA ATG ACA CG) for disruption by *HIS3.* The *kan^r^* gene was used to disrupt *YPT32* using the oligos *YPT32-kan^r^*-pro (TGA TAA AGA GCG AAC CAA GCA TAT TGT TTT CCA AGA GCA TAG GCC ACT AGT GGA TCT G) and *YPT32kan^r^*-term (GAC AGA TAT GCA TGA AAC CAT GCG ACC TTA GTA GGG CAG CTG AAG CTT CGT ACG C). PCR and transformation of yeast strains were performed as described by [@B6]. Selection of G418 resistance was performed as described ([@B75]). Deletions were confirmed using Southern blotting ([@B58]) and/ or PCR. For the confirmation of *YPT31* disruption by *HIS3*, the following oligos were used: *YPT31*dv (GCC GGA TCC GAT CTA TCC CAG CGC AAT C) and *HIS3*-1 (CAC TTG CGA TTG TGT GGC CTG). *YPT32* deletion was confirmed using the oligos *YPT32*dv (GCA TGG TTC GCG CTG GAA AGA G) and *HIS3*-1, or *kan^r^*-1 (GTG AGA ACT GTA TCC TAG CA) for deletion by *HIS3* and *kan^r^*, respectively.

Site-directed Mutagenesis and Plasmid Construction
--------------------------------------------------

The *ypt32-A141D* mutant was made by site-directed mutagenesis using the method of [@B31] in the *Escherichia coli* phagemid vector pBluescript II SK +. Mutagenesis was performed on a partial *YPT32* gene generated by PCR using the oligonucleotides *YPT32*-b4 (CTC CGG TGT GGG TAA ATC TA) and *YPT32*-XbaI (GCG TCT AGA GGT TAG TAA TAA ATA ACT TG). The PCR fragment was cut with EcoRI and XbaI, and cloned EcoRI to XbaI in BSIISK. The resulting *YPT32* gene is truncated by 144 bp at its 5′ end. The mutagenic oligonucleotide was *YPT32*A-D (CCA ACC GAT GAA GAC AAA AAT TTC GCA ATG). The mutation was confirmed by sequencing, and the gene was transferred to the integrating vector pRS306 ([@B65]) using EcoRI and XbaI. This construct was cut with BglII and targeted to the chromosome in the NSY290 strain (*Δypt31::HIS3*) as previously described ([@B63]).

Centromeric *YPT31* expression plasmids were constructed as follows: A 1.26-kb HindIII-PstI genomic DNA fragment containing the *YPT31* promoter and structural gene was cloned into the multiple cloning site of pBluescript II SK +. The insert was then excised as a BamHI-HindIII fragment and cloned into either pRS316 (*URA3*) or pRS315 (*LEU2*) ([@B65]) to yield pRS316::*YPT31* (pNS220) and pRS315::*YPT31* (pNS221).

Protein Purification
--------------------

The yeast proteins Ypt31, Ypt32, and Sec4 were expressed in bacteria as glutathione S--transferase (GST) fusions in the bacterial pGEX-KG expression plasmid (reference numbers *YPT31*, pNS210; *YPT32*, pNS211; *SEC4*, pNS212) ([@B21]). This was done by PCR amplification of plasmid DNA using oligonucleotides that engineer BamHI and XbaI sites upstream and downstream of the *YPT* genes. In all three cases, the BamHI site was engineered directly upstream of the start codon such that the junction between GST and Ypt protein was identical in all cases. The following oligonucleotides were used (restriction sites are bold): *YPT31*-1 (GCC **GAA** **TCC** ATG AGC AGC GAG GAC TAC GGG) and *YPT31*-2 (CGC **TCT** **AGA** GTC ATT CAC ATG CAA GTG CGC), *YPT 32*-1 (GCC **GGA** **TCC** ATG AGC AAC GAA GAT TAC GGA TAC G) and *YPT32*-XbaI (GCG **TCT** **AGA** GGT TAG TAA TAA ATA ACT TG), *SEC4*-1 (GCC **GGA** **TCC** ATG TCA GGC TTG AGA ACT GTT TC), and *SEC4*-2 (CGC **TCT** **AGA** CCT GAT GAA AAT ACC TTC CAG A). The PCR product was digested with BamHI and XbaI, and cloned into the pGEX-KG vector, which was similarly cut. The construction of the GST--Ypt1 fusion protein has been previously described ([@B28]). GST-Ypt fusion proteins were purified as previously described ([@B28]).

Preparation of Antiserum Directed Against Ypt31 and Affinity Purification
-------------------------------------------------------------------------

Purified fusion protein was used to immunize two New Zealand white rabbits as previously described ([@B24]). The resulting antisera were tested by immunoblotting of whole cell yeast extracts. Anti-Ypt31p polyclonal antibodies were affinity purified using recombinant Ypt31p immobilized on cyanogen bromide--activated Sepharose (3 mg Ypt31p/ml packed bead volume) as described by the manufacturer (Pharmacia Biotechnology Inc., Piscataway, NJ). For affinity purification, crude rabbit serum was diluted 1:2 with buffer A (20 mM Tris, pH 7.5, 0.1 M NaCl) and bound to immobilized Ypt31p in batch for 3 h at room temperature. Beads were then washed with 20 column volumes of buffer A followed by 10 column volumes of buffer B (20 mM Tris, pH 7.5, 0.5 M NaCl). Immobilized antibody was then eluted with 0.1 M glycine, pH 2.5, elluate was collected in 0.9-ml fractions, which were immediately neutralized with 0.1 ml 1 M Tris, pH 8. Fractions were extensively dialyzed against TBS (10 mM Tris, pH 7.4, 0.1 M NaCl) and then against TBS-40% (vol/vol) glycerol and stored at −20°C. All experiments shown used affinity-purified antibodies.

Immunoblot Analysis
-------------------

Cell extracts or purified Ypt proteins were resolved on 12% SDS--polyacrylamide gels and transferred onto Immobilon-P in transfer buffer (25 mM Tris, 380 mM glycine, 20% methanol) at 80 V for 1 h at 4°C. Membranes were treated with Ponceau S for 5 min, destained with water, and blocked for 1 h in TBST--5% milk (10 mM Tris, pH 7.4, 100 mM NaCl, 0.05% \[vol/vol\] Tween-20). Membranes were then probed with anti-Ypt31 (1:2,000) or anti-Ypt1 (1:2,000) in TBST--1% milk for 1 h at room temperature. The membrane was then washed 5 times with TBST--1% milk over the course of 30 min and probed with HRP-conjugated anti--rabbit IgG secondary at 1:5,000 for 1 h. Membranes were washed in TBST--1% milk six times over the course of 30 min and developed for chemiluminescence as described (Amersham International). Chemiluminescence was quantified by densitometry using a Howtek Scanmaster3+ densitometer.

Immunofluorescence and Electron Microscopy
------------------------------------------

Immunofluorescence microscopy was done as previously described ([@B53]), with some modifications. Cells were grown in synthetic minimal medium to an OD~600~ between 0.5 and 1. Cells were fixed by directly adding 37% formaldehyde to the growth medium to a final concentration of 3.7%. After 15 min at 26°C, cells were pelleted at 2,500 rpm in a low-speed centrifuge and then resuspended in an equal volume of 3.7% formaldehyde in 0.1 M potassium phosphate, pH 6.5, and fixed for an additional 2 h at 26°C with rotation. Cells were washed twice with an equal volume of 0.1 M phosphate buffer and transferred to 1.5-ml Eppendorf tubes. Cells were pelleted at ∼5,000 rpm in a tabletop centrifuge and washed a final time in 1 ml of spheroplasting buffer (1.4 M sorbitol, 0.1 M potassium phosphate, pH 7.5). After this final wash, cells were resuspended in spheroplasting buffer to a final concentration of 1 OD~600~/200 μl buffer, and 1 M DTT was added to a final concentration of 5 mM. Spheroplasting was initiated by the addition of 10 μl of yeast lytic enzyme (20,000 U/ml) and carried out at 37°C for 1--2 h. Spheroplasts were harvested by centrifugation at 3,000 rpm in a tabletop centrifuge and washed twice in 200 μl spheroplasting buffer. After the final wash, cells were resuspended in 200 μl spheroplasting buffer. 20 μl of cells were seeded onto either multiwell slides or coverslips that had been coated with poly-[l]{.smallcaps}-lysine (0.1% wt/vol). Cells were allowed to settle for 5 min, buffer was aspirated, and the slides were allowed to air dry for 20 min.

Slides were blocked for 5 min with TBS-BSA (10 mM Tris, pH 7.4, 100 mM NaCl, 2.5 mg/ml BSA), after which primary affinity-purified antibodies in TBS-BSA were applied at the following dilutions: anti-Ypt1p, 1:500; anti-Ypt31p, 1:200. Incubation was carried out for 1 h. Slides were washed 12 times by rapid aspiration and addition of TBS-BSA. Secondary antibody fluoresceinated anti-rabbit FAB was then applied at 1:50 dilutions. Rhodamine-phalloidin was used at a dilution of 1:20 as described ([@B53]). Coverslips or slides were mounted as described ([@B53]) and viewed using a microscope (model Axioskop; Carl Zeiss, Inc., Thornwood, NY) equipped with a 100-W power source for epifluorescence (Carl Zeiss, Inc.).

Electron microscopy was performed on cells grown in synthetic minimal medium, where indicated cells were shifted to 37°C for 2 hours. Processing of cells for EM and quantification of micrographs was carried out as previously described ([@B30]). The following rules were used to distinguish small vesicles, large vesicles, and cisternae/Berkeley bodies, all of which were manifested as electron-dense profiles of varying size and shape. Profiles were counted as small vesicles when they were 50--80 nm in diameter and as large vesicles if they were 100--150 nm in diameter. Linear membranous profiles \>200 nm and \<1 μm in length were scored as cisternae. Multilamellar circular membranous structures \>200 nm in diameter were scored as Berkeley bodies ([@B47]). Thirty cells were counted for each strain. Immunoelectron microscopy was conducted as previously described ([@B43]). The use of anti-Ypt1p antibodies for immunoelectron microscopy has also been described ([@B52]).

Cell Labeling and Immunoprecipitation
-------------------------------------

Cell labeling and immunoprecipitation were carried out as previously described ([@B27]) with the following modifications: For the induction of invertase, cells were grown to mid-logarithmic phase in SD plus 2% dextrose (wt/vol) minus methionine and cysteine at 26°C and washed twice in SD plus 0.1% dextrose (wt/vol) minus methionine and cysteine. Cells were resuspended in the same medium at a density of 1 OD~600~ U/ml and incubated at 26°C for 30 min to induce invertase. For spheroplasting, Zymolyase 100T was used at a concentration of 1.0 μg/OD~600~ U of cells. Pulse-chase experiments were quantified using a phosphorimaging system (DuPont/New England Nuclear, Wilmington, DE). Quantification in the text refers to results presented in corresponding figures.

Results
=======

Two New Functionally Homologous Exocytic Ypt GTPases
----------------------------------------------------

We have found two new *YPT* genes as high-copy suppressors of the dominant *YPT1D124N* mutation ([@B28]; Jones, S., and N. Segev, manuscript in preparation). The sequences of the two genes revealed that they belong to the Ypt/rab family of GTPases and that their protein products share 81% identity and 90% similarity (Fig. [1](#F1){ref-type="fig"} *A*). These genes were submitted to the yeast database by other researchers as *YPT31* or *YPT8* ([@B33]) and *YPT32*. (These sequence data are available from GenBank/EMBL/ DDBJ under accession numbers U18778 and X72834, respectively.) The high degree of sequence similarity between the two genes suggested that they might be functionally homologous. The protein products are most similar to the mammalian rab11 GTPase and to *Schizosaccharomyces pombe* Ypt3 (62 and 63% identity, respectively), and their closest *Saccharomyces cerevisiae* homologues are Ypt1 and Sec4 (42--46% identity; Ypt1 and Sec4 share 48% identity). Phylogenetic analysis of all Ypt proteins present in *S. cerevisiae*, using the completed genome sequence available for this organism, and of their human homologues reveals that Ypt/rab GTPases fall into two subfamilies: exocytic and endocytic/vacuolar. The two new Ypt proteins, Ypt31 and Ypt32, seem to belong to the subfamily of exocytic Ypt/rab GTPases (Fig. [1](#F1){ref-type="fig"} *B*). We wished to study the possible role of Ypt31 and Ypt32 proteins in the yeast exocytic pathway since very little is known about components that regulate the secretory steps between those regulated by the Ypt1 and Sec4 GTPases.

To determine whether the *YPT31* and *YPT32* genes are essential for viability, we studied the effect of their deletion on cell growth. *YPT31* was deleted by precise replacement of its entire coding region with the *HIS3* gene, and *YPT32* by its precise replacement with either the *kan^r^* or the *HIS3* gene. The replacement of both genes was confirmed by PCR analysis (not shown). Cells deleted for either *YPT31* or *YPT32* alone are viable (see Fig. [3](#F3){ref-type="fig"} *B*). Thus, neither gene is essential for viability. The effect of deletion of *YPT31* and/or *YPT32* genes on cell growth was determined also by analyzing the ability of the cells to lose the *YPT31* gene carried on a plasmid marked with *URA3.* Cells deleted for *YPT31* and carrying the *YPT31* gene on a plasmid can grow on 5-FOA plates, indicating that the cells can lose the plasmid (Fig. [1](#F1){ref-type="fig"} *C*, *top line*). However, cells deleted for both *YPT31* and *YPT32* genes and carrying the *YPT31* gene on a plasmid do not grow on 5-FOA plates, indicating that they cannot lose the *YPT31* gene carried by the plasmid (Fig. [1](#F1){ref-type="fig"} *C*, *middle line*). These cells can grow on 5-FOA plates if they contain in addition another plasmid (marked with *LEU2*) that carries the *YPT31* gene (Fig. [1](#F1){ref-type="fig"} *C*, *bottom line*). Together, these results show that while neither gene is required for cell growth, at least one of them is necessary for viability. These data and the high degree of homology between the two genes suggest that they are functional homologues or perform overlapping functions.

Ypt31/32 GTPases Exhibit a Novel Intracellular Localization Pattern
-------------------------------------------------------------------

To study the intracellular expression and localization of Ypt31/32 GTPases, we purified recombinant Ypt31 and Ypt32 proteins and raised polyclonal antibodies against Ypt31p. The bacterially purified proteins both migrate on a denaturing gel with apparent molecular mass of ∼23 kD, with Ypt31p migrating somewhat more slowly than Ypt32p (Fig. [2](#F2){ref-type="fig"} *A*, *top*). The antibody recognizes both bacterially produced proteins by immunoblot analysis, but its level of detection of Ypt31p is about threefold higher than that for Ypt32p. The antibodies did not react with the closest Ypt31/32p homologues, Ypt1p and Sec4p (Fig. [2](#F2){ref-type="fig"} *A*, *bottom*). The affinity-purified anti-Ypt31p antibodies reveal one protein band in wild-type yeast cells. This band corresponds to Ypt31p since it is absent in cells deleted for the *YPT31* gene and is more abundant in cells expressing the *YPT31* gene on a 2μ high copy number plasmid. However, the antibodies also recognize Ypt32p when it is expressed from a 2μ plasmid in a *YPT31*-null strain (Fig. [2](#F2){ref-type="fig"} *B*). Comparing the levels of Ypt31 and Ypt32 proteins in cells expressing them from a 2μ plasmid, in a strain deleted for *YPT31* gene, suggests that Ypt31 is considerably more abundant than Ypt32 in yeast cells (about 5- to 10-fold more abundant, taking into account a threefold better detection of Ypt31p by the antibody). Fractionation of yeast cells followed by immunoblot analysis revealed that ∼90% of the Ypt31p molecules are associated with the membranous fraction (100,000 *g* pellet; data not shown).

We examined the localization of Ypt31/32 proteins in growing wild-type yeast cells using immunofluorescence microscopy with the affinity-purified anti-Ypt31/32 antibodies. Filamentous actin (F-actin) was also visualized to label the presumptive bud site and identify cells undergoing cytokinesis. Two prominent staining features were observed; punctate staining, which is typical of the yeast Golgi ([@B64]; [@B16]; [@B55]), and localization to the presumptive bud site and small buds. Sec4p, which resides on late secretory vesicles, also localizes to small buds ([@B45]). The asymmetric distribution of Ypt31p seen in some unbudded cells is due to the localization of this protein to the bud emergence site, which is marked by F-actin. In addition, late mitotic cells frequently showed Ypt31p localization at the site of cytokinesis (Fig. [2](#F2){ref-type="fig"} *C*). Thus, periods in the cell cycle which are characterized by highly polarized growth, late G1/early S phase and cytokinesis ([@B35]), show polarized Ypt31p staining. In contrast, cells in early G1 (unbudded cells with random actin staining) and late G2 (large-budded cells) show punctate Ypt31p staining. These patterns of staining primarily reflect the distribution of Ypt31p since there is almost no signal in cells deleted for the *YPT31* gene. However, it seems that the localization of Ypt32p is similar to that observed for Ypt31p since the very faint staining seen in *ypt31-null* cells is similar to that seen in wild-type cells (data not shown). The fact that the Ypt31p localization resembles both that of Golgi and late secretory vesicles suggests that Ypt31/32 GTPases localize to a late secretory compartment. Since to the best of our knowledge, no Golgi marker, including the *trans*-Golgi Kex2 protease, has been shown by immunofluorescence microscopy to be dramatically concentrated in sites of cell growth, we suggest that the polarized staining of Ypt31p reflects its localization to post-Golgi secretory vesicles. These vesicles were shown by electron microscopy to localize to sites of cell growth ([@B39]; [@B9]).

The ypt32-A141D Mutation Confers a Block in the trans-Golgi Compartment
-----------------------------------------------------------------------

To study the role of Ypt31/32 GTPases in the yeast secretory pathway, we constructed a conditional lethal *ypt32A141D* recessive mutation that confers temperature sensitivity for growth in cells deleted for the *YPT31* gene. This mutation was constructed by analogy to the *ypt1-A136D* mutation, which was characterized previously in our lab ([@B27]). The mutation changes an amino acid that is conserved in structure (a small, uncharged residue, A, S, or G) among Ypt/rab proteins (Fig. [3](#F3){ref-type="fig"} *A*). By analogy to the tertiary structure of ras, this amino acid is predicted to be on the hydrophobic face of a conserved amphipathic α-helix ([@B69]). This mutation conferred a tight and rapid block of Ypt1p function ([@B27]). Since the level of Ypt1-A136D mutant protein does not change after incubation at the restrictive temperature ([@B27]), it is likely that this mutation encodes a protein that undergoes a temperature-sensitive change in function. The analogous mutation in *SEC4-*G147D (*sec4-8*; [@B42]) also confers a tight temperature-sensitive block in secretion of invertase (data not shown). We predicted that introducing an analogous mutation in other Ypt/rab proteins might result in a temperature-sensitive loss-of-function phenotype. As shown below, the *ypt32-A141D* mutation confers conditional blocks in growth and secretion. Therefore, this substitution has proven to be a useful tool for obtaining a conditional mutation in three different Ypt proteins and might be useful for determining the functions of other Ypt/rab proteins or of ras-like proteins in general.

Cells carrying the *ypt32-A141D* mutation and deleted for the *YPT31* gene exhibit a tight temperature sensitivity for growth at 37°C (Fig. [3](#F3){ref-type="fig"} *B*). We tested the effect of this mutation on the transport of two secreted proteins, invertase and α-factor, and a vacuolar protein, CPY. To determine the effect of the *ypt31Δ/32-A141D* (*ypt31/32*) mutation on protein transport at the permissive temperature, we compared the processing of invertase at 26°C in wildtype and mutant cells. Cells were labeled at 26°C for 7 min, and then chased for 10 or 30 min. Spheroplasts were separated from periplasmic contents, and invertase was immunoprecipitated from both fractions and analyzed by gel electrophoresis. It is possible to distinguish between invertase that resides in early secretory compartments (ER; core glycosylated and *cis*-Golgi; α-1,6-mannosylated), invertase in *medial*- or *trans*-Golgi (α-1,3-mannosylated), and secreted invertase (periplasmic). After 10 min of chase, wildtype cells secrete most (∼90%) of the invertase labeled during the pulse. *ypt31/32* mutant cells also secrete most of the invertase (81%), which is fully glycosylated, but only after 30 min of chase (Fig. [4](#F4){ref-type="fig"} *A*). Thus, the *ypt31/32* mutant cells display a kinetic defect in secretion at the permissive temperature.

To determine the effect of the *ypt31/32* mutations on protein transport at the nonpermissive temperature, the different secretory compartments were marked with radiolabeled transport intermediates of the marker proteins using a brief pulse under permissive conditions, and the cells were then chased at the nonpermissive temperature. First, to examine the effect of the mutation on the ability of cells to secrete a marker protein, we followed the processing of invertase at the restrictive temperature. Wild-type and mutant cells were labeled at the permissive temperature (26°C) for 7 min and then shifted to the nonpermissive temperature (37°C) and chased for 10 or 30 min. In wildtype and mutant cells, the various secretory compartments were loaded with the different forms of invertase during the pulse, as seen by the presence of core- and fully glycosylated invertase (Fig. [4](#F4){ref-type="fig"} *B*, *chase time 0′*). After a 10-min chase of wild-type cells, all the forms that were present during the pulse were converted to the mature fully glycosylated form and were secreted. (87% was secreted.) Invertase in *ypt31/32-*mutant cells shifted to the nonpermissive temperature was also converted to the fully glycosylated form, as shown by reprecipitation of invertase from mutant cells with antisera specific for *cis*- and *medial*Golgi modifications (α-1,6- and α-1,3-mannose linkages) (Fig. [4](#F4){ref-type="fig"} *C*). However, mutant cells at the nonpermissive temperature exhibited a complete block of secretion of invertase even after 30 min of chase (93% remained inside the cells; Fig. [4](#F4){ref-type="fig"} *B*). This secretory defect is much more dramatic than the decrease in the rate of secretion observed at the permissive temperature. These results suggest that the *ypt31/32* mutations confer a primary block in the secretion of invertase in a step between the *medial*-Golgi and the plasma membrane.

To distinguish between a block in the *medial*- or *trans*Golgi compartments, which contain α-1,3-mannosyltransferase and Kex2 protease, respectively, we followed the processing of α-factor. This protein contains recognition sites for the Kex2 protease. Wild-type, *ypt31-Δ/ypt32-A141D*, and *sec4-G147D* mutant cells were labeled at the permissive temperature (26°C) for 7 min, shifted to the nonpermissive temperature (37°C), and chased for 10 or 30 min. Cells were separated from the medium, and α-factor was immunoprecipitated and analyzed by gel electrophoresis. In wild-type and mutant cells, the various secretory compartments were loaded with the different forms of α-factor during the pulse, as seen by the presence of core, α-1,6modified, α-1,3-modified, and mature forms (Fig. [5](#F5){ref-type="fig"}, *chase time 0′*). In wild-type cells, even after a short chase, all of these forms were converted to the mature form. The limitation of using α-factor as a marker is that the mature form cannot be quantitatively detected, probably because of degradation, and the analysis of the processing is thus restricted to determining the disappearance of the intermediate forms. *sec4-G147D* mutant cells exhibited a defect in secretion of mature α-factor consistent with a defect in the fusion of post-Golgi vesicles with the plasma membrane (Fig. [5](#F5){ref-type="fig"} *A*, *mαf*). Like *sec4-G147D* mutant cells, *ypt31-Δ/ ypt32-A141D* mutant cells were defective in the secretion of mature α-factor peptide but were also partially defective at earlier stages of the secretory pathway. In addition, both mutants secreted some α-factor that had not received proteolytic processing, indicating an additional defect in the function of the *trans*-Golgi (Fig. [5](#F5){ref-type="fig"} *A*, *arrows*). However, this *trans*-Golgi processing defect is probably minor and secondary, since the immature forms accumulated after the chase in both mutant strains represent only a minor fraction of the α-factor labeled during the pulse (time 0). Because a significant amount of α-factor is secreted under the conditions of this experiment, we examined the secretion of α-factor after a 2-min preshift to the nonpermissive temperature. Under these conditions, less α-factor is secreted to the medium in both the *sec4* and *ypt31/32* mutants (Fig. [5](#F5){ref-type="fig"} *B*), although the *ypt31/32* mutant is still slightly leaky. Together, the results suggest that *ypt31/32* mutant cells, like *sec4* mutant cells, are defective in processes that occur in the exit from the *trans*-Golgi, or within this compartment.

We wished to determine whether transport to the vacuole is affected by the *ypt31/32* mutations. Proteins destined for the vacuole are sorted from secreted proteins at the *trans*-Golgi compartment ([@B20]). Thus, CPY processing is dependent on the function of *SEC* genes that function at all steps between ER and the *trans*Golgi, and on *VPS* genes that regulate sorting at the *trans*Golgi, but not on SEC genes that function at the post- *trans*-Golgi step of the exocytic pathway ([@B68]). To examine CPY processing, the secretory compartments were loaded during a pulse at the permissive temperature with the various labeled forms of CPY (the p1 form in the ER, p2 form in the Golgi, and mature form in the vacuole) and then shifted to 37°C for the chase. In wild-type cells, all of the CPY was converted to the mature form after 30 min of chase. *ypt31/32* mutant cells sorted most of their CPY to the vacuole as seen by the accumulation of the mature form (80% when compared to wildtype). However, CPY processing was somewhat slower in mutant cells than in wild-type cells: The ER form (p1) was still present after 10 min chase, and some CPY remained as the p2 form after 30 min of chase at the nonpermissive temperature in mutant, but not in wild-type cells (Fig. [6](#F6){ref-type="fig"}). Mutations in *VPS* genes result in secretion of the p2 form of CPY ([@B5]). Since no CPY was secreted by *ypt31/32* mutant cells at the nonpermissive temperature, Ypt31/32 GTPases do not seem to function in the sorting of vacuolar proteins (Fig. [6](#F6){ref-type="fig"}). These results suggest that there is no major defect in the processing of vacuolar CPY in *ypt31/32* mutant cells. The defect revealed by the accumulation of the p2 form might reflect a secondary defect at the *trans*-Golgi compartment after a 30-min incubation at the nonpermissive temperature, or a decrease in the rate of CPY processing through the whole pathway in mutant cells. Alternatively, Ypt31/32 GTPases might have a role in more than one step between the *medial*-Golgi and the plasma membrane.

We have established that the Ypt31/32 GTPases function in the yeast exocytic pathway. Our results suggest that these GTPases function at the level of the *trans*-Golgi compartment, in *trans*-Golgi to plasma membrane transport, and perhaps also in *medial*- to *trans*-Golgi transport. The secretory phenotype conferred by the *ypt31/32* mutation resembles that exhibited by the analogous *sec4* mutation. However, the electron microscopic analysis of the *ypt31/32* mutant cells described below indicates that Ypt31/32 GTPases function at a step distinct from that regulated by Sec4p.

Accumulation of Aberrant Golgi Structures in ypt31/32 Mutant Cells
------------------------------------------------------------------

The fact that the secretory defect of *ypt31/32* mutant cells is similar to that of *sec4* cells could indicate that Ypt31/32 and Sec4 GTPases function in the same process, i.e., fusion of secretory vesicles with the plasma membrane. Alternatively, they might have roles in two different secretory steps or substeps, e.g., Ypt31/32 might function in vesicle budding or fusion at the *trans*-Golgi compartment, and Sec4 in fusion of *trans*-Golgi--derived vesicles with the plasma membrane. In general, *sec* mutants have been shown to accumulate aberrant membranes of secretory compartments that precede the step in which they first function ([@B47]; [@B30]). Thus, *sec4* mutant cells have been shown to accumulate secretory vesicles ([@B46]; [@B76]). To determine whether *ypt31/32* mutant cells accumulate such vesicles or whether they accumulate other membranous structures, cells were shifted from the permissive temperature (26°C) to the nonpermissive temperature (37°C) for 2 h and examined by electron microscopy. We quantified the accumulation of various aberrant membrane structures: small vesicles (50--80 nm), aberrant Golgi (cisternae and Berkeley bodies), and large vesicles (100--150 nm) (Fig. [7](#F7){ref-type="fig"} *E*). We compared the effect of the *ypt1-A136D* mutation and the analogous mutations in *YPT31/32* and *SEC4* on the type of membrane accumulated. Unlike *sec4-G147D* mutant cells, which accumulate post-Golgi vesicles almost exclusively (Fig. [7](#F7){ref-type="fig"}, *D* and *E*), *ypt31Δ/32-A141D* mutant cells exhibited an abundance of aberrant Golgi-like structures (Fig. [7](#F7){ref-type="fig"}, *C* and *E*) and some ER (Fig. [7](#F7){ref-type="fig"} *C*, *arrowhead*). This phenotype is also distinct from that observed for *ypt1A136D* mutant cells, which accumulate ER membranes and small secretory vesicles (Fig. [7](#F7){ref-type="fig"} *B*), but not Golgi.

*ypt31-Δ/32-A141D* mutant cells display a steady state increase in the frequency of Golgi cisternae even at the permissive temperature (26°C) when compared to wild-type cells (Fig. [8](#F8){ref-type="fig"} *A*, *B*, and *D*). This result indicates that the kinetic defect in protein transport seen in the mutant at the permissive temperature (Fig. [4](#F4){ref-type="fig"} *A*) is accompanied by some accumulation of Golgi cisternae. However, a more dramatic change was observed in mutant cells shifted to the nonpermissive temperature (37°C). Under this growth condition, the total number of aberrant Golgi profiles roughly doubled, and the population became dominated by Berkeley bodies (60% of total at 37°C vs. 30% of total at 26°C; Fig. [8](#F8){ref-type="fig"} *D*). These multilamellar structures, in which one cisterna appears to engulf another, were first observed in *sec7* and *sec14* mutant cells, which are defective in Golgi function ([@B47]). Mutant Golgi structures are larger than those seen in wild-type cells (385 ± 107 nm, and 298 ± 81 nm, respectively), are frequently observed to form stacks, and are occasionally swollen to ∼100 nm at their periphery (Fig. [9](#F9){ref-type="fig"} *B*), indicating a possible defect in vesicle formation.

A combination of immunofluorescence and immunoelectron microscopy was used to identify the origin of the aberrant membrane structures accumulated in *ypt31Δ/32A141D* mutant cells. In electron micrographs, these structures usually seem to cluster within one area of the cell. A similar clustering was visualized by immunofluorescence microscopy as a change in the Ypt1p staining pattern, from the wild-type punctate to a mutant asymmetric pattern (Fig. [8](#F8){ref-type="fig"} *E*). To show that the structures visualized by immunofluorescence correspond to those seen by electron microscopy, we performed immunoelectron microscopy using affinity-purified antibodies against Ypt1p. After a 60-min incubation of the *ypt31/32* mutant cells at 37°C, the cisternal and spherical structures that accumulate in these cells both contain Ypt1p on their membranes (Fig. [10](#F10){ref-type="fig"}). These membranes do not label with antibodies against the vacuolar H^+^-ATPase subunit Vph1p (data not shown), indicating that they differ from the multilamellar structures that accumulate in the class E *vps28* mutant ([@B57]). Because the aberrant membrane structures present in *ypt31Δ/32-A141D* mutant cells appear to label with the established Golgi marker Ypt1p ([@B52]), and because similar structures are seen in *sec* mutants defective in Golgi function ([@B47]), we conclude that these structures are Golgi cisternae.

To further test this interpretation, we constructed a *ypt31Δ/32-A141D*, *sec1-1* triple mutant and determined the type of aberrant membranes that accumulated. The *sec1-1* mutant has been shown to accumulate post-Golgi vesicles similar to those observed in the *sec4-8* mutant ([@B22]). If Ypt31/32p function in exit from the Golgi, the triple mutant should display the *ypt31/32* mutant phenotype at the nonpermissive temperature. As controls we examined the *ypt31/32* mutant and a triple mutant strain that had been transformed with *YPT31* on a single copy vector. (This strain is hereafter referred to as the *sec1-1* mutant.) While the *sec1-1* mutant accumulated post-Golgi vesicles (Fig. [11](#F11){ref-type="fig"} *B*), the triple mutant accumulated aberrant Golgi structures similar to those observed in the *ypt31/32* mutant (Fig. [11](#F11){ref-type="fig"}, *C* and *A*, respectively). Thus, the *ypt31/32* double mutation is epistatic to the *sec1-1* mutation. However, the *sec1-1* mutation appears to exacerbate the *ypt31/32* phenotype. First, while the *ypt31/32* mutant accumulated some ER (see Fig. [7](#F7){ref-type="fig"} *C*, *arrowhead*), the triple mutant accumulated significant levels of fenestrated ER membranes that were continuous with the nuclear envelope (Fig. [11](#F11){ref-type="fig"} *C*, *arrowheads*). Second, the triple mutant was inviable at 30°C, while both *ypt31/32* and *sec1-1* mutant cells were viable at this temperature (data not shown). *sec1-1*, like all late *sec* mutants, is defective in the uptake of the lipophilic dye FM4-64 from the plasma membrane, indicating a possible function for Sec1p in membrane recycling ([@B74]). One explanation for the synergistic effect in the triple mutant is that membrane accumulation due to the *ypt31/32* mutations is enhanced by the defect in membrane recycling imposed by the *sec1-1* mutation. Together, the ensemble of results presented show that Ypt31/32 GTPases function in a secretory step distinct from that regulated by Sec4p, probably in the exit of secretory proteins from the *trans*-Golgi compartment.

Discussion
==========

In this study, we show that two novel GTPases, Ypt31p and Ypt32p, have a role in the yeast exocytic pathway, in a step between those regulated by two other Ypt/rab GTPases, Ypt1p and Sec4p. The sequence similarity between Ypt31p and Ypt32p, and the fact that the presence of only one of them is required for cell viability, strongly suggests they are functional homologues. We propose that Ypt31p and Ypt32p function in exit from the *trans*-Golgi compartment (Fig. [12](#F12){ref-type="fig"}). This conclusion is based on phenotypic analysis of inactivating mutations in these genes, a comparison of *ypt1*, *ypt31/32*, and *sec4* mutant strains by electron microscopy and epistasis analysis using the *ypt31/32* mutant and a late secretory *sec1* mutant.

The inference that Ypt31/32 proteins are required for execution of a step(s) in the exocytic pathway is based on the tight, late-Golgi block in the secretion of invertase exhibited by *ypt31/32* mutant cells. Thus, fully glycosylated invertase (α-1,6- and α-1,3- mannosylated) accumulates in these cells, indicating that the block must be after invertase arrives at the *medial*-Golgi compartment. As described below, our results using two other markers are most consistent with a role of Ypt31/32 GTPases in transport of proteins from the *trans*-Golgi compartment. First, the resemblance of the defect of α-factor processing in *ypt31/32* mutant cells to that of *sec4* mutant cells suggests that the primary secretory defect is at or beyond the *trans*-Golgi compartment. Second, there is no major block in transport of CPY to the vacuole, nor is CPY secreted to the medium. Finally, the *ypt31/32* mutant phenotype is epistatic to that of *sec1-1.* Thus, Ypt31/32 proteins function upstream of the post-Golgi vesicle targeting step, and by inference upstream of Sec4p. These data suggest that the defect in the *ypt31/32* mutant cells occurs after the arrival of secretory proteins at the *trans*-Golgi compartment and during their transport to the plasma membrane, but not to the vacuole. *ypt31/32* mutant cells do show slight defects of CPY and α-factor transport during earlier steps of the secretory pathway and some accumulation of ER membranes, but these effects are probably indirect. A defect in a late secretory step might affect an earlier step indirectly, by blocking the recycling of transport factors back to an early compartment.

One possible mechanism that would involve a role for Ypt31/32p in exit from the *trans*-Golgi is that these GTPases function in the budding of secretory vesicles from the *trans*-Golgi compartment (Fig. [12](#F12){ref-type="fig"} *A*). This suggestion is based on the accumulation of aberrant Golgi structures and the lack of accumulation of transport vesicles in *ypt31/ 32* mutant cells, both at the permissive temperature (when the secretory phenotype is very mild) and after a long incubation at the nonpermissive temperature. In contrast, defects in Ypt1 and Sec4 proteins result in accumulation of 50- and 100-nm vesicles, respectively. Two observations support a role for Ypt31/32p in budding from the *trans*Golgi. First, *ypt31/32* mutant Golgi profiles are elongated relative to wild-type Golgi profiles. This result is consistent with a block in export of membranous material. Second, swollen membranous lobes as large as 100 nm, occasionally seen at the periphery of the mutant Golgi structures (see Fig. [9](#F9){ref-type="fig"} *B*, *open arrow*), are consistent with a defect in membrane fission required for vesicle budding. An analogous electron microscopic approach was used to classify the early ER-to-Golgi Sec proteins into two distinct sets that function either in vesicle formation or in vesicle fusion ([@B30]); this study was supported by subsequent in vitro analyses ([@B56]; [@B37]). Similarly, in vitro analysis is needed to confirm a role for Ypt/rab proteins in vesicle budding. For example, mammalian cell-free systems for post-TGN secretory vesicle formation ([@B70]; [@B29]; [@B12]) could be used to analyze the role of Ypt31/32 proteins, or their mammalian homologues, in this process. Ypt/rab proteins have previously been implicated in vesicle budding, although the evidence was not conclusive. First, rab1 was suggested to act at the vesicle budding stage during in vitro ER-to-Golgi transport ([@B51]; [@B49]); however, its yeast homologue, Ypt1p, has a somewhat different function ([@B56]; [@B62]). We have suggested that Ypt1p has a single site of action at the *cis*-Golgi compartment but is required for two successive transport steps (ER to *cis*-Golgi and *cis*- to *medial*-Golgi), regulating both fusion with and budding from the *cis*-Golgi ([@B27]). Second, rab6 is associated with a protein complex, and using immunodepletion, this complex was shown to be needed for TGNderived vesicle budding in vitro. However, rab6 itself was not shown to be essential for this process ([@B29]). Third, GDP dissociation inhibitor abolishes vesicle formation in a cell-free system, indicating a possible role for rabs in this process ([@B12]).

If Ypt/rab GTPases function both in vesicle budding and in vesicle targeting/fusion, how might they be acting? It has been suggested that Ypt/rab proteins regulate the formation of a SNARE complex that mediates vesicle fusion ([@B13]; [@B67]; [@B60]). Another GTPase subfamily, Arf/Sar1, was shown to regulate coat assembly and disassembly during vesicle budding ([@B61]). A common theme is that GTPases regulate protein complex assembly and/or disassembly. We hypothesize that Ypt/rab GTPases regulate such events during both vesicle budding and vesicle fusion, perhaps by interacting with the same set of partner proteins in each case. For example, disassembly of the SNARE complex may be required to reactivate the SNAREs for a new reaction cycle ([@B40]). Ypt/rab proteins might regulate this disassembly during vesicle budding, while regulating assembly of the SNARE complex during vesicle fusion.

Previous studies have conclusively demonstrated a role for Ypt/rab proteins in regulating vesicle targeting (see introduction). Thus, an alternative interpretation of our data is that Ypt31/32, like Ypt1 and Sec4 GTPases, promote a targeting/fusion event in the Golgi. Two such mechanisms can be envisioned: (*a*) Ypt31/32 proteins may regulate an event in which cisternae fuse directly. This model implies that the fusion event does not involve vesicles because vesicles do not accumulate in *ypt31/32* mutant cells. In addition, this alternative model implies the existence of an additional compartment beyond the Kex2p-containing *trans*Golgi compartment in yeast because our results indicate that Ypt31/32 proteins mediate a step beyond the Kex2pcontaining compartment. Since there is no evidence for nonvesicular fusion within the yeast Golgi, nor for the existence of an additional secretory compartment beyond the Kex2p-containing compartment, this explanation currently seems unlikely. However, below we discuss a modification of this idea that involves a possible late-Golgi/ early endosome compartment. (*b*) Ypt31/32 proteins may regulate the fusion of retrograde vesicles that recycle components essential for the *trans*-Golgi budding machinery (Fig. [12](#F12){ref-type="fig"} *B*). If the level of these components is limiting at the *trans*-Golgi, a tight and rapid exocytic block will occur when Ypt31/32 proteins are inactivated. Moreover, if the formation of such vesicles requires continuous input of membrane from exocytosis, they would not accumulate appreciably upon inactivation of Ypt31/32p. Although uncoupling of recycling to the *trans*-Golgi from exocytosis was shown for the *ypt6* null mutant ([@B71]), we cannot rule out the possibility that these processes are coupled in our experimental system.

Immunofluorescence microscopy revealed a novel staining pattern for Ypt31/32p: a polarized staining in sites of cell growth, plus a random punctate staining characteristic of the Golgi. This localization pattern shares similarities with the Ypt1p and Sec4p localization patterns, which are distinct from each other ([@B64]; [@B45]). The Ypt31/32p staining pattern is consistent with the possibility that these proteins act in secretory steps between those regulated by the Ypt1 and Sec4 GTPases. Ypt31/32p staining does not overlap significantly with that of the *trans*-Golgi marker Kex2p, nor with early Golgi markers (Ypt1p, Mnn1p, Pmr1p; data not shown). The reason for the lack of overlap with Kex2p staining is not clear. One possibility is that Ypt31/32 proteins associate with the Golgi transiently to promote vesicle budding and then remain bound to transport vesicles that are translocated to sites of exocytosis. This possibility is supported by the localization of Ypt31/32p to sites of cell growth. Localization to sites of cell growth has been shown for postGolgi secretory vesicles in yeast ([@B39]; [@B9]). The electron microscopic analysis of *ypt31/32* mutant cells suggests that Ypt31/32 proteins function to promote the formation of vesicles from the *trans*-Golgi, but if Ypt31/32 proteins are present on exocytic transport vesicles, it is possible that these proteins also function after vesicle budding.

The closest homologues of Ypt31/32 GTPases in other species are mammalian rab11 and *S. pombe* Ypt3p. *S. pombe* Ypt3p was shown to be essential for cell viability ([@B41]). The rab11 amino acid sequence is 62% identical to that of Ypt31/32 proteins, but it is not clear that this level of sequence homology implies functional homology. Rab11 was shown to be associated with the TGN and TGN-derived vesicles of both the constitutive and regulated secretory pathways ([@B73]; [@B12]; [@B26]). The localization of rab11 is thus in agreement with our suggestion concerning the localization of Ypt31/32 GTPases and might indicate that rab11 and Ypt31/32 are functional homologues. Recently, rab11 protein was implicated in controlling traffic through the recycling endosome, which recycles plasma membrane proteins ([@B72]). If recycling to the *trans*-Golgi is coupled with exit from this compartment, it is not clear which of these reactions Ypt31/32p or rab11 regulates. One possibility is that exocytosis and endocytosis converge in a late-Golgi/early-endosomal compartment and that transport through this compartment is regulated by these GTPases. In mammalian cells there is evidence for the existence of an endosomal intermediate for a subset of post-Golgi exocytic transport events ([@B17]; [@B34]). In such a case, some of the membranous structures that we observe in the *ypt31/32* mutant cells may represent yeast analogs of this compartment. In the future, the use of newly defined protein markers of the yeast endocytic pathway ([@B10]; [@B23]) will allow us to test this idea using the *ypt31/32* mutant.

We present a model for the role of four Ypt GTPases in the yeast secretory pathway (Fig. [12](#F12){ref-type="fig"}). In this model, Ypt1p functions in ER to *cis*-Golgi and *cis*- to *medial*-Golgi transport, mediating vesicle targeting in the ER to *cis*-Golgi step; Ypt31/32 proteins function in vesicle budding from, or targeting to, the *trans*-Golgi; and Sec4p functions in targeting of secretory vesicles to the plasma membrane. There is one step, *medial-* to *trans*-Golgi, for which no Ypt GTPase has been assigned. Although it is possible that Ypt31/ 32p also have a role in this step (see partial early secretory defect, Figs. [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}), they do not seem to be essential for this step, based on the α-factor secretory defect (Fig. [5](#F5){ref-type="fig"}). We searched the complete *S. cerevisiae* genome sequence for the presence of additional exocytic Ypt proteins and did not find any. However, Ypt6/rab6 proteins have similar homology to both the endocytic and exocytic Ypt/rab proteins, and the function of these Ypt/rab family members is uncertain. While Ypt6p was implicated in vacuolar protein sorting ([@B71]), rab6 was suggested to be involved in intra-Golgi transport or in budding of vesicles from the TGN ([@B29]; [@B38]). One possibility is that Ypt6p functions in the *medial*- to *trans*-Golgi step in yeast.

Studying Ypt31/32 in conjunction with the two other known exocytic Ypt GTPases, Ypt1p and Sec4p, should allow us to analyze possible interactions between these regulators. For example, we found *YPT31* and *YPT32* as suppressors of dominant *YPT1* mutations (Jones, S., and N. Segev, manuscript in preparation). In addition, questions can now be asked regarding the specificity of accessory factors that regulate the nucleotide cycling of Ypt/rab proteins. Moreover, since very little is known about protein transport out of the yeast Golgi compartment, Ypt31/32 proteins will serve as a handle for the further characterization of this process.
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Yeast Strains

  Strain       Genotype                                                                              Source
  --------- -- ---------------------------------------------------------------------------------- -- ----------------------------------------------
  NSY128:      *MATα, ade2, his3Δ200, leu2-3,112, lys2-801, ura3-52*                                 DBY4975 David Botstein
  NSY125:      *MATa, his4-539, lys2-801, ura3-52*                                                   DBY1034 David Botstein
  NSY290:      NSY128, *Δypt31::HIS3*                                                                This study
  NSY296:      NSY128, *Δypt32::HIS3*                                                                This study
  NSY301:      NSY290 transformed with *pRS316-YPT31*                                                This study
  NSY302:      NSY301, *Δypt32::KANr*                                                                This study
  NSY306:      NSY302, transformed with *pRS315-YPT31*                                               This study
  NSY313:      *MATα, ade2, his3Δ200, leu2-3,112, lys2-801, ura3-52, Δypt31::HIS3, ypt32-A141D*      This study
  NSY348:      *MATa, lys2, his4, ura3-52, Δypt31::HIS3, ypt32-A141D*                                This study
  NSY368:      *MATα, leu2, ura3-52, suc2Δ9, Δypt31::HIS3, ypt32-A141D, sec1-1*                      This study
  PNY404:      *MATα, his4-619, sec4-8*                                                              Peter Novick, Yale University, New Haven, CT
  PNY504:      *MATα, leu2-3,112, ura3-52, suc2Δ9, sec1-1*                                           Peter Novick
  NSY222:      *MATα, his4, ura3-52, ypt1-A136D*                                                     [@B27]
  JK9-3d:      *MATa/α, leu2/leu2, his4/his4, trp1/trp1, ura3-52/ura3-52*                            Mike Hall, Basel, Switzerland
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The *YPT31* and *YPT32* genes encode two functionally homologous exocytic GTPases. (*A*) Comparison of the amino acid sequences of Ypt31 and Ypt32 proteins. The predicted protein sequence of Ypt32 was compared to Ypt31 using the MegAlign program (DNAStar Inc., Madison, WI, Clustal method with the PAM250 residue weight table). Identities are shaded with solid black, and residues conserved to within two distance units are shaded. Overall, the two proteins are 81.1% identical and 89.6% similar when compared using the bestfit program (Genetics Computer Group, Madison, WI). (*B*) Ypt31 and Ypt32 proteins belong to a subfamily of exocytic Ypt GTPases by phylogenetic analysis of the Ypt/rab family of small GTPases. The predicted amino acid sequence of Ypt31 and Ypt32 were compared to all other Ypt proteins, using the completed *S. cerevisiae* genome sequence and their human homologues. The analysis shows that Ypt/rab proteins fall into two functional subfamilies: those involved in endocytosis and vacuolar protein sorting (*Endocytosis-Vac*.) and those involved in exocytosis. Sequences were aligned as above. The scale at the bottom indicates the number of substitutions between sequences. *hum.*, *Homo sapiens*; *H-ras*, Harvey murine sarcoma virus ras protein; all other sequences, *Saccharomyces cerevisiae.* These sequence data are available from GenBank/EMBL/DDBJ under accession numbers: Ypt31, U18778; Ypt32, X72834; rab11, X56740; Ypt7, X68144; rab7, U44104; Ypt1, X00209; rab1a, M28209; Sec4, M16507; Ypt6, U17244; rab6a, M28212; Ypt51, X76173; Ypt52, X76174; Ypt53, X76175; rab5b, X54871; and H-ras, X00740. (*C*) Requirement of *YPT31* or *YPT32* genes for cell viability. The *YPT31* gene was precisely deleted using the *HIS3* gene, and this strain was transformed with a *URA3*-marked *CEN* vector containing the *YPT31* gene under control of its own promoter (NSY301, *first row*). This strain (NSY301) was subsequently deleted for the *YPT32* gene using the *KAN^r^* gene as a dominant delectable marker (NSY302, *middle row*). Finally, this strain (NSY302) was transformed with a second plasmid marked with *LEU2* and carrying the *YPT31* gene (NSY306, *bottom row*). The three strains were grown in synthetic media maintaining selection for plasmids. Serial dilutions of cells were then spotted onto either SD or SD-FOA and grown at 26°C. Cells deleted for both genes do not grow on SD-FOA plates, indicating that they cannot lose the *URA*-marked *YPT31* plasmid unless they carry also the *LEU*-marked *YPT31* plasmid.
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The *YPT32-A141D* mutation is in a conserved residue and confers a tight conditional growth phenotype. (*A*) Comparison of the amino acid sequence of the α-helix 5 region in Ypt/rab and ras proteins. Arrow indicates conserved residue, which when mutated to Asp results in temperature-sensitive function in Ypt1 (*ypt1-A136D*), Ypt32 (*ypt32-A141D*), and Sec4 (*sec4-8*, *sec4-G147D*). (*B*) The *ypt32-A141D* mutation confers a temperaturesensitive growth phenotype in cells deleted for the *YPT31* gene. Serial dilutions of wild-type (NSY128), *Δypt31* (NSY290), *Δypt32* (NSY296), and *Δypt31,ypt32-A141D* (NSY313) cells were spotted on YPD plates and incubated at 26° or 37°C.
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Ypt31 protein is found at sites of polarized cell growth. (*A*) Characterization of anti-Ypt31 antibodies. Antibodies raised against Ypt31p react with Ypt31p, and to a lesser degree with Ypt32p, but not Ypt1 and Sec4 proteins. Bacterially purified Ypt1, Ypt31, Ypt32, and Sec4 proteins were analyzed by SDS-PAGE followed by either Coomassie staining (1 μg protein in each lane) or Western blotting (5 ng protein in each lane) using anti-Ypt1 or anti-Ypt31 antibodies. (*B*) Detection of Ypt31 and Ypt32 proteins in yeast cell extracts: Ypt31p is present in excess of Ypt32p in wild-type yeast cells. Wild-type (NSY128) or deletion strains (*Δypt31*, NSY 290 and *Δypt32*, NSY296) transformed with the indicated plasmids were grown in synthetic medium maintaining selection for deletions and plasmids present. Cells were lysed by the addition of 2× Laemmli buffer and boiling for 5 min. 0.5 OD~600~ U of lysate from each strain was then subjected to immunoblot analysis using affinity-purified anti-Ypt31 antibodies. (*C*) Localization of the Ypt31 protein in yeast cells using immunofluorescence microscopy. Diploid yeast cells (JK9-3d) were double stained with rhodamine-phalloidin (to visualize filamentous actin) and with anti-Ypt31 antibodies. Cells were also photographed using Nomarski optics to distinguish budded from unbudded cells (*top*). Arrowheads indicate polarized Ypt31 staining, which localizes to regions of cell growth in (from left to right) a cell in late G1, a cell in early S phase, and a cell undergoing cytokinesis. Bar, 10 μm.
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![*ypt31-Δ/ypt32-A141D* mutant cells exhibit a tight conditional secretory block of invertase transport downstream of the *medial*-Golgi. Wild-type (NSY349, *left*) and mutant (NSY348, *right*) cells were labeled for 7 min at 26°C. Cells were then chased at 26°C (*A*) or shifted to 37°C (*B*) with prewarmed media and chased for the indicated times. At each time point, cells were separated from the periplasmic fraction by spheroplasting, lysates were prepared, and samples were immunoprecipitated with antiinvertase antibodies. Equal portions of precipitate from each time point were then separated on 8% SDS--polyacrylamide gels. (*C*) Intracellular invertase from the indicated time point was divided into three equal portions and precipitated with antisera against invertase, α1,6-mannose, or α1,3-mannose residues as indicated. ER (*core*), Golgi (*outerchain*), and cytoplasmic (*cyto.*) forms of invertase are indicated in the left margin.](JCB.jedd4){#F4}

![*ypt31-Δ/ypt32-A141D* (NSY313) and *sec4-G147D* (PNY404) mutant cells both show defects in the *trans*-Golgi processing and transport of α-factor at the nonpermissive temperature. (*A*) The indicated strains (*wild-type* is NSY128) were labeled for 7 min at 26°C, shifted to 37°C with prewarmed media, and chased for the indicated times. Cells were separated from medium by centrifugation and processed for immunoprecipitation with anti--α-factor antibodies. (*B*) Alternatively, cells were preshifted to 37°C for 2 min with prewarmed medium, labeled for 7 min and chased for the indicated times. Only mature peptide is shown, as higher molecular weight forms of α-factor behave similarly to those shown in *A*, except that both mutants secreted proportionally less high molecular weight α-factor after the preshift, and all strains (including wild-type) show translocation and processing defects. Positions of ER (*core*), *cis*-Golgi (*α16*), *medial*-Golgi (*α1-3*), and *trans*-Golgi (*mαf*) forms are noted in the left margin. Arrows in the right margin indicate secreted α-factor that was not fully processed in the *trans*-Golgi.](JCB.jedd5){#F5}

![*ypt31-Δ/ypt32-A141D* mutant cells do not exhibit a major defect in targeting of CPY to the vacuole at the nonpermissive temperature. Extracts from the 37°C samples shown in Fig. [4](#F4){ref-type="fig"} were subjected to precipitation with anti-CPY antibodies and resolved on 8% SDS--polyacrylamide gels. Positions of the ER (*p1*), Golgi (*p2*), and vacuolar (*m*) forms of CPY are indicated in the left margin.](JCB.jedd6){#F6}

###### 

*ypt31-Δ/ypt32A141D* mutant cells accumulate aberrant Golgi-like structures at the nonpermissive temperature. Wild-type and three strains mutated at the analogous conserved residue in *YPT1*, *YPT32*, and *SEC4* were analyzed by electron microscopy. Electron micrographs of representative cells are shown for the following strains: (*A*) *wildtype* (NSY128), (*B*) *ypt1A136D* (NSY222), (*C*) *ypt31Δ/ypt32-A141D* (NSY348), and (*D*) *sec4-G147D* (PNY 404). Cells were grown at 26°C, shifted to 37°C for 2 h, and then processed for thin section electron microscopy. Arrows point to membranous structures unique to each strain. Arrowheads indicate ER. *G*, wild-type Golgi cisterna (shown in detail in Fig. [9](#F9){ref-type="fig"} *A*, *second panel from left*); *V*, vacuole; *n*, nucleus. (*E*) Quantification of the distinct membranous structures that accumulate in the different mutant strains: small vesicles (50--80 nm), Golgi (cisternae or Berkeley bodies), and large vesicles (100--150 nm). Bars represent the mean number of structures in 30 cell sections. Data is normalized to density per cubic micrometer for vesicle populations and density per 10 μm^2^ for cisternae and Berkeley bodies. Error bars represent one standard deviation (see Materials and Methods for details of the quantification procedure). The relatively high standard deviations are probably due to the aggregation of the aberrant membranes to one side of the cell, resulting in cell sections that are either rich in or devoid of the corresponding membranous structure. Bar, 1 μm.
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![Details of Golgi structures in wild-type and *ypt31-Δ*/*ypt32-A141D* mutant cells. (*A*) Electron microscopy of wild-type (NSY128) cells. Wild-type Golgi is usually observed as an elongated or cup-shaped single cisternae ([@B52]), which are not always continuous (*third panel from left*) because of fenestration ([@B54]). (*B*) Enlarged *ypt31-Δ*/*ypt32-A141D* mutant (NSY348) Golgi structures. Long arrows indicate an example of stacked cisternae in the mutant strain. Short arrows indicate spherical and tear drop--shaped Berkeley bodies. The tear-shaped structure suggests that Berkeley bodies are derived from individual cup-shaped cisternae that fuse at the rim (see *curved arrow* for a possible intermediate in this process). Open arrow indicates swelling to 100 nm at the cisternal rim, which may represent an intermediate preceding vesicle formation by membrane fission. Arrowheads indicate rare 100nm vesicles seen in the vicinity of cisternae, for size comparison with structures that look like budding vesicles. Note also the increased length of cisternal profiles in the mutant strain compared to *wild-type.* Regions of four different cells are shown for each strain. Bars, 0.5 μm.](JCB.jedd9){#F9}

###### 

*ypt31-Δ/ypt32A141D* mutant cells accumulate Golgi membranes at the permissive temperature and Berkeley bodies at the nonpermissive temperature. Electron microscopy of (*A*) *wild-type* (NSY128), (*B*) *ypt31-Δ*/*ypt32-A141D* mutant strain (NSY348) at 26°C, and (*C*) *ypt31-Δ/ypt32A141D* mutant strain (NSY348) at 37°C. Arrows indicate a single Golgi cisterna in a wild-type cell and regions of Golgi accumulation in mutant cells. *v*, vacuole; *n*, nucleus. (*D*) Quantification of cisternal profiles and Berkeley bodies in wildtype cells at 26°C and *ypt31Δ*/*ypt32-A141D* mutant (NSY348) cells at 26° and 37°C. The percentage of the total structures counted that are cisternal is indicated by the gray bar, and the percentage of Berkeley bodies is represented by the black bar. At the permissive temperature, the mutant shows a fivefold increase in the frequency of Golgi profiles, the majority of which (70% of total) are cisternal. After 2 h at 37°C, the number of Golgi profiles has doubled and the population is dominated by Berkeley bodies (60% of total). (*E*) Immunofluorescence microscopy using anti-Ypt1p antibodies ([@B64]). (*1*) *wild-type* cells (NSY128) grown at 26°C; (*2*) the *ypt31-Δ/ypt32-A141D* mutant (NSY348) grown at 26°C; or (*3*) shifted to 37°C, for 90 min; (*4*) the same cells shown in *3* photographed with Nomarski optics to show the contours of the cells. Bars: (*A--C*) 1 μm; (*E*) 10 μm.
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![Ypt1p is present on aberrant Golgi membranes accumulated in the *ypt31-Δ*/*ypt32-A141D* mutant cells. *ypt31-Δ/ypt32A141D* mutant cells were grown at 26°C and shifted to 37°C for 1 h before fixation and processing for immunoelectron microscopy using anti-Ypt1p antisera. Gold particles are seen specifically labeling stacked cisternae (*long arrow*) and spherical structures (*short arrow*). Note a strand of ER that is unlabeled (*arrowhead*) and the lack of gold particles over mitochondria (*m*) and cytosol. Bar, 250 nm.](JCB.jedd10){#F10}

![The *ypt31-Δ*/ *ypt32-A141D*, *sec1-1* triple mutant accumulates Golgi structures. Electron microscopy of (*A*) *ypt31-Δ*/*ypt32A141D* (NSY348) mutant, (*B*) the *ypt31-Δ*/*ypt32A141D*, *sec1-1* triple mutant transformed with *YPT31* on a single copy vector (phenotypically *sec1-1*), and (*C*) the *ypt31-Δ/ypt32*-*A141D*, *sec1-1* (NSY368) triple mutant. Arrows point to structures characteristic of each strain; arrowheads indicate ER that can be seen in continuity with the nuclear envelope in the triple mutant, but are also present in *ypt31-Δ/ ypt32-A141D* mutant cells. *n*, nucleus. Bar, 1 μm.](JCB.jedd11){#F11}

![Model for the action of Ypt GTPases in the yeast exocytic secretory pathway. Ypt1p and Sec4p are essential for three secretory steps: ER to *cis*-Golgi, *cis*- to *medial*-Golgi, and *trans*Golgi to the plasma membrane ([@B47]; [@B27]). For two of these steps, it was shown that Ypt1 and Sec4 proteins function in targeting of ER- and *trans*-Golgi--derived vesicles, respectively ([@B47]; [@B56]; [@B62]). (*A*) Ypt31/32 proteins are suggested to have a role in promoting vesicle budding from the *trans*-Golgi. (*B*) Alternatively, Ypt31/32 may regulate a fusion step between the *trans*-Golgi and retrograde vesicles derived from a recycling compartment (see Discussion).](JCB.jedd12){#F12}
